文献速递糖尿病肥胖与代谢综合征

达格列净对2型糖尿病血糖控制及心血管危险因素的真实世界研究

The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study.
PubMed 文献 · Diabetologia · 2019-01-10

基于苏格兰国家糖尿病登记数据库(2004年至2016年中),对8566名使用达格列净的患者进行真实世界观察性研究,中位暴露210天。结果显示达格列净暴露与HbA1c、收缩压、体重和BMI的降低相关,且至少与临床试验中的幅度相当,并 prevented 了研究期间HbA1c和收缩压的预期上升。

要点

  • 达格列净真实世界暴露12个月时HbA1c效应估计为-15.14 mmol/mol(-1.39%)。
  • 前3个月收缩压下降-4.32 mmHg并维持,BMI和体重在6个月时稳定下降。
  • 累积药物暴露对安全性结局无显著影响,但检测效能有限。

核心结论

  • 达格列净暴露与HbA1c、收缩压、体重和BMI的降低相关,幅度至少与临床试验相当。
  • 达格列净 prevented 了研究期间HbA1c和收缩压的预期上升。

研究设计与样本

  • 真实世界观察性研究,使用苏格兰国家糖尿病登记数据库(2004年至2016年中)数据。
  • 纳入8566名使用达格列净的2型糖尿病患者,中位暴露210天。
  • 采用混合效应回归模型调整个体内时间轨迹,并用Cox比例风险模型评估安全性结局。

主要发现

  • 3个月暴露后HbA1c粗变化为-10.41 mmol/mol(-0.95%);12个月粗变化为-12.99 mmol/mol(-1.19%)。
  • 12个月时达格列净暴露效应估计为-15.14 mmol/mol(95%CI -15.87, -14.41)(-1.39% [95%CI -1.45, -1.32]),此后维持。
  • 前3个月收缩压下降-4.32 mmHg(95%CI -4.84, -3.79)并维持。
  • BMI和体重在6个月时稳定下降-0.82 kg/m2(95%CI -0.87, -0.77)和-2.20 kg(95%CI -2.34, -2.06)并维持。
  • eGFR在3个月时初始下降-1.81 ml min-1 [1.73 m]-2(95%CI -2.10, -1.52),此后变化不一。

临床怎么用

  • 真实世界数据支持达格列净在2型糖尿病患者中改善血糖控制及心血管危险因素的效果。
  • 达格列净可预防HbA1c和收缩压随时间的预期上升。
  • 需关注eGFR初始下降,但累积暴露未显示显著安全性信号。

局限性

  • 观察性研究设计,可能存在残余混杂。
  • 检测安全性结局的统计效能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is indicated for improving glycaemic control in type 2 diabetes mellitus. Whether its effects on HbA1c and other variables, including safety outcomes, in clinical trials are obtained in real-world practice needs to be established. METHODS: We used data from the comprehensive national diabetes register, the Scottish Care Information-Diabetes (SCI-Diabetes) collaboration database, available from 2004 to mid-2016. Data within this database were linked to mortality data from the General Registrar, available from the Information Services Division (ISD) of the National Health Service in Scotland. We calculated crude within-person differences between pre- and post-drug-initiation values of HbA1c, BMI, body weight, systolic blood pressure (SBP) and eGFR. We used mixed-effects regression models to adjust for within-person time trajectories in these measures. For completeness, we evaluated safety outcomes, cardiovascular disease events, lower-limb amputation and diabetic ketoacidosis, focusing on cumulative exposure effects, using Cox proportional hazard models, though power to detect such effects was limited. RESULTS: Among 8566 people exposed to dapagliflozin over a median of 210 days the crude within-person change in HbA1c was -10.41 mmol/mol (-0.95%) after 3 months' exposure. The crude change after 12 months was -12.99 mmol/mol (-1.19%) but considering the expected rise over time in HbA1c gave a dapagliflozin-exposure-effect estimate of -15.14 mmol/mol (95% CI -15.87, -14.41) (-1.39% [95% CI -1.45, -1.32]) at 12 months that was maintained thereafter. A drop in SBP of -4.32 mmHg (95% CI -4.84, -3.79) on exposure within the first 3 months was also maintained thereafter. Reductions in BMI and body weight stabilised by 6 months at -0.82 kg/m2 (95% CI -0.87, -0.77) and -2.20 kg (95% CI -2.34, -2.06) and were maintained thereafter. eGFR declined initially by -1.81 ml min-1 [1.73 m]-2 (95% CI -2.10, -1.52) at 3 months but varied thereafter. There were no significant effects of cumulative drug exposure on safety outcomes. CONCLUSIONS/INTERPRETATION: Dapagliflozin exposure was associated with reductions in HbA1c, SBP, body weight and BMI that were at least as large as in clinical trials. Dapagliflozin also prevented the expected rise in HbA1c and SBP over the period of study.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. McGurnaghan SJ, Brierley L, Caparrotta TM, et al. The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study. Diabetologia. 2019. PMID: 30631892. doi:10.1007/s00125-018-4806-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。